KRAS and non-small cell lung carcinoma: The phase II CodeBreaK100 trial demonstrated an ORR of 37.1% and a median duration of response (DoR) of 11.1 months for sotorasib in KRAS G12C-mutated NSCLC, although intracranial outcomes were not assessed [85].